header-news
Managing named-patient programmes
Friday, 30 May 2008

Project managing a named-patient programme can be time-consuming and complex. Many pharmaceutical companies choose to outsource the management of the supply of their drug to a specialist third party company who are considered experts in controlling the supply of medicines on a named-patient basis.

Read more...
 
Drug regime gets phase II trials
Wednesday, 16 January 2008
A new drug treatment regime for patients living with different forms of lymphoma is undergoing phase II clinical trials in the US, it has been announced.

Drug firms Pharmion Corporation and MethylGene are examining how two of their drugs - Pharmion's Vidaza and Methyl's MGCD0103 - perform when given to patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.
Read more...
 
Heart attack drug trials to launch
Tuesday, 15 January 2008
Phase IIb trials of a medicine designed to prevent heart attacks are to begin in the spring after positive results from phase IIa trials.

Drugmaker DeCode Genetics revealed that it plans to enrol 400 subjects in a new trial designed to collect data on "its pharmacokinetic and pharmacodynamic parameters, as well as safety and tolerability".
Read more...
 
Colorectal cancer enters phase II trials
Monday, 14 January 2008
A new drug designed to treat patients with colorectal cancer is to undergo phase IIb trials later this year, it has been announced.

Nektar Therapeutics said that NKTR-102, an irinotecan, will be examined at more than 40 centres across the world in order to collect data on its safety and efficacy when used to treat patients who have solid tumours in the bowel or rectum.
Read more...
 
More...
<< Start < Prev 1 2 Next > End >>

Results 1 - 24 of 47